the recent identification and purification of other biologically active cytokines , such as tumor necrosis factor and interleukin-2 , and of monoclonal antibodies that recognize unique cell surface antigens on renal carcinoma cells , provide exciting possibilities for combination regimens with various interferon species .
C0007134
renal carcinoma
C0021747
interferon